Assay News and Research

RSS

Nanocell COVID-19 vaccine elicits potent neutralizing response

A new study describes the high level of neutralizing antibodies elicited by a nanocell vaccine against SARS-CoV-2 in vitro, in vivo, and human studies.

11 Apr 2022

Chromatin accessibility as an early marker of severe COVID-19

A new study explores the possible use of chromatin remodeling in predicting a severe clinical trajectory for COVID-19.

11 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

A novel PLpro inhibitor as a broad-spectrum anti-coronavirus agent

Researchers identify a potentially effective compound against COVID-19 against the SARS-CoV-2 PLpro.

10 Apr 2022

Evaluating immunogenicity after BNT162b2 booster vaccination

Researchers assessed the levels of IgG and IgA antibodies in sera samples from healthcare workers before vaccination, after the first vaccine dose, after eight months, and after a booster shot.

8 Apr 2022

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

In a new study, researchers characterized over 100 SARS-CoV-2-specific CD4+ T-cell epitopes.

8 Apr 2022

Improved seroprevalence and antibody response after third COVID-19 vaccination

Researchers evaluated the immunogenicity of a third COVID-19 vaccination in antibody deficient subjects.

8 Apr 2022

Neutralization potency against the Omicron variant of naturally expressed MBC-derived IgG antibodies from vaccinated individuals

Researchers have shown how the Omicron variant of the SARS-CoV-2 successfully evaded a large fraction of antibodies derived from memory B cells, giving rise to a reduced, but incomplete immune escape.

8 Apr 2022

Study on the viral dynamics of Omicron and Delta infected individuals

Researchers examine the infectious periods in vaccinated individuals infected with the SARS-CoV-2 Omicron and Delta variants.

7 Apr 2022

SARS-CoV-2 detected using smartphone biosensor

Researchers describe the use of RT-LAMP in combination with particle diffusometry to detect SARS-CoV2 in saliva samples.

7 Apr 2022

Axol Bioscience Raises £3.2 Million GBP (c. $4.2 million USD)

Axol Bioscience Ltd. today announced that it has raised £3.2 million GBP in the extension of its previous funding round, bringing the total raised to £7 million GBP.

From Axol Bioscience Ltd 7 Apr 2022

Study suggests blunted serological responses not responsible for COVID-19 mortality

A new study investigated serological profiling to determine the antibody responses in critically ill COVID-19 positive and negative patients.

7 Apr 2022

Efficacy of SARS-CoV-2 hyperimmune globulin in treatment of severely immunocompromised hospitalized COVID-19 patients

Researchers conducted a controlled, double-blinded Phase III trial to evaluate the efficacy of SARS-CoV-2) hyperimmune globulin in immunocompromised hospitalized COVID-19 patients.

7 Apr 2022

Specialist assay kits and microplates for cancer research

Porvair Sciences will exhibit its latest assay kits and microplates for cancer and life science research at the American Association for Cancer Research (AACR) meeting in New Orleans, USA from the 8th – 13th April 2022.

From Porvair Sciences Limited 7 Apr 2022

SARS-CoV-2 spike S375F mutation triggered the explosive spread of Omicron

In a recent study posted to the bioRxiv* preprint server, researchers investigated the mutation in the viral spike (S) protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1 variant (referred to as Omicron in the present study) that is responsible for the variant’s virological features.

7 Apr 2022